Rajini Chandrasegaram
Researcher Beacon
Seminars
Thursday 16th April 2026
2025 Review & 2026 Outlook Across AD, PD, ALS & MSA
9:00 am
- From expanding pipelines to next‑generation mechanisms: A cross‑disease view of how AD, PD, ALS and MSA pipelines are evolving, with biologics and advanced modalities reshaping the neuro drug landscape
- Clinical momentum accelerating across neurodegeneration: Key trends from 2025 trial activity, including the rise of early‑phase innovation, shifting global trial geographies, and pivotal readouts influencing development decisions
- Strategic forces driving the future of neuro R&D: How partnerships, licensing, investment shifts, and 2026 regulatory milestones are redefining opportunity across the neuro space from commercial strategy to AI‑enabled discovery
